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COMMENT
Are we over-treating with checkpoint inhibitors?
Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates
high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need
for long-term treatment duration, using evidence from melanoma research, both published and in process.
British Journal of Cancer (2019) 121:629–630; https://doi.org/10.1038/s41416-019-0570-y
MAIN
Anti-PD-1 antibodies (pembrolizumab and nivolumab) are
licensed to be administered to metastatic melanoma patients
until disease progression. Multiple anti-PD(L)-1 antibodies are
being licensed to treat various different cancer types, all with
prolonged durations of treatment to 2 years or more for
responding patients. The question of whether anti-PD(L)-1 therapy
needs administering continuously to generate an immune
response is taxing the global oncology community. Chronic
administration generates a signiﬁcant burden for patients and
healthcare systems, entailing multiple clinic visits and the risk of
chronic, life changing and sometimes life-threatening immune-
mediated toxicities. The health-economic impact is substantial,
which not all healthcare systems can absorb.1
The ﬁrst checkpoint inhibitor to enter the clinic was the anti-
CTLA-4 antibody ipilimumab. In contrast to anti-PD(L)-1 anti-
bodies, ipilimumab is administered over 12 weeks only, and
around 20% of patients will sustain durable remissions in the
absence of ongoing infusions. CTLA-4 and PD-1 differ in their T-
cell receptor role and function, yet there is no biological evidence
justifying continuous therapy with anti-PD(L)-1 antibodies.2
Indeed, contrary evidence is now accumulating.
Long-term follow-up of metastatic melanoma patients treated
in the ﬁrst prospective trials evaluating anti-PD-1 suggests
treatment to progression may not be justiﬁed.2–4 In the
Keynote-001 pembrolizumab trial, 105 of 655 (17%) recruited
patients had a complete response and 67 of 105 stopped
pembrolizumab while still in complete response, mostly due to
patient choice. The 2-year disease-free survival rate from the time
of complete response was 90% for all, whether or not they
stopped treatment.5 In the Keynote-006 trial comparing pembro-
lizumab with ipilimumab as ﬁrst line immunotherapy for meta-
static melanoma, the planned treatment with pembrolizumab was
2 years.6 A total of 104 of 556 (19%) patients completed the
planned course. After following the 104 patients for a median of
9 months, their progression-free survival (PFS) was 91%: 95% for
complete responders, 91% for partial responders, and 83% for
those with stable disease. A total of 17% of patients experienced
severe (grade 3/4) toxicity during treatment. Based on these data,
many clinicians and patients are electing to stop treatment at 2
years.3,6
For metastatic melanoma, 40% of patients can expect to
respond to anti-PD-1 antibodies and therefore are likely to be
eligible to continue treatment to 2 years or more.3,4 Most
responses to anti-PD-1 antibodies occur within 6 months of
starting treatment and there is growing motivation to stop
treatment before 2 years.7 A recent retrospective study deter-
mined that ‘real-life’ duration of treatment is shorter than that
reported in clinical trials; patients with a complete response (CR)
compared with a partial response (PR) or stable disease may have
a lower risk of relapse off therapy. In those with CR, the risk of
progression was signiﬁcantly higher in those treated for
<6 months compared with those treated for >6 months.8 Another
retrospective review of 104 progression-free metastatic mela-
noma patients undergoing FDG-PET/CT after 1 year of anti-PD-1
antibodies reported that complete metabolic response (CMR) was
associated with 2-year PFS of 96%, compared with 49% in those
patients whose scans did not show CMR (HR [hazard ratio] 0.06,
95% CI [conﬁdence interval] 0.02–0.23), so other tools may offer
value in tailoring treatment in the future.9 Even so, national
reimbursement models are generally licence-driven and neither
stopping early, nor treatment re-challenge, may actually be
permitted. There is clearly a need to generate high-quality
evidence to deﬁne early stopping rules.
The CheckMate153 study is the only randomised study
published to date speciﬁcally evaluating duration of anti-PD-1
therapy. CheckMate153 compared treatment until progression
with 12 months of nivolumab in patients with advanced non-small
cell lung cancer (NSCLC). In this study, 220 patients receiving
nivolumab who were progression-free at 12 months were
randomised to continue until progression, or to stop treatment;
patients in the discontinuation arm were allowed to re-start
nivolumab at progression. Initial results10 reported better PFS with
continuous versus 12-months treatment: median PFS was not
reached in the continuous arm compared with 10.3 months (95%
CI 6.4–15.2) in the discontinuation arm (HR 0.42, 95% CI 0.25–0.71).
Despite PFS differences, overall survival did not show a
statistically signiﬁcant difference between the two treatment
arms (HR 0.63, 95% CI 0.33–1.20), although the data are immature.
Whether these results are generalisable to other tumour
types needs to be determined and two key prospective clinical
trials are now under way in metastatic melanoma. Both
are pragmatic and use standard of care, government-funded
anti-PD-1 therapy.
The Canadian STOP-GAP study (NCT02821013) is currently
assessing intermittent versus continuous treatment with anti-PD-1
inhibitors, with a primary endpoint of overall survival. In this trial,
614 patients are being randomised in the ﬁrst 16 weeks of anti-
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PD-1 treatment to either standard 2 years of treatment
or treatment to maximal tumour response with retreatment
at the time of progression. Maximal tumour response is
determined by at least two radiological measurements 3 months
apart. STOP-GAP therefore is primarily evaluating the role of re-
challenge rather than the speciﬁc question of optimal treatment
duration.
The UK National Institute for Health Research (NIHR) portfolio
DANTE trial (ISRCTN15837212) is randomising metastatic melanoma
patients receiving anti-PD-1 therapy who are progression-free at
12 months to either stop (with re-challenge allowed on progression)
or continue treatment as per standard use. This non-inferiority trial
has a primary endpoint of PFS. Patients are being registered in the
ﬁrst year of treatment, with a plan to randomise 1208 patients at
12 months. Opportunities are being explored to utilise this unique
trial to evaluate biomarkers of treatment response as well as toxicity,
including genetic signatures, circulating tumour DNA, gut microbiota
and 18F-FDG PET/CT.
We encourage patients and investigators alike to support
prospective randomised controlled trials like DANTE and
STOP-GAP, generating the evidence needed to ensure safe,
effective and affordable treatment for our patients now and in the
future.
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